COLD-FX®
CVT-E002
Natural Health Product
(NPN 80002849)

Each capsule is certified to contain 200 mg of CVT-E002, a proprietary ChemBioPrint® (CBP®) product containing greater than 80% poly-furanosyl-pyranosyl-saccharides extracted by an aqueous method from Panax quinquefolius (North American ginseng, root).

As a ChemBioPrint product, proprietary standardization technology has been used to identify and isolate the active ingredient (CVT-E002) and ensure consistency from batch to batch. CVT-E002 is scientifically proven to provide health benefits by enhancing the immune system’s viral-fighting Natural Killer cells and macrophages.

Learn more about ChemBioPrint.

Recommended use or purpose: To help reduce the frequency, duration and severity of cold and flu symptoms by boosting the immune system.

Dosing, Administration and Storage:
Dosage form: capsule
Quantity per dosage unit: 200 mg
Route of administration: oral
Recommended dose: Adults and children (12 years and older): Take one capsule two times per day.
Shelf Life: 5 years at room temperature.

Risk Information:
Individuals requiring anti-coagulant therapy such as warfarin should avoid use of COLD-FX.
Do not use if pregnant or breastfeeding.
Not recommended for individuals with impaired liver or renal function.
Do not exceed the recommended daily dose.
Individuals with known allergies to ginseng should avoid use of COLD-FX.

For Full Monograph Information for CVT-E002 (COLD-FX):
The American Botanical Council (ABC), North America's leading nonprofit research and education organization on herbal medicines, has independently produced a Therapeutic Monograph and Clinical Overview for CVT-E002 (COLD-FX), written by Bruce Barrett, MD, PhD and Donald J. Brown, ND. Five independent U.S. physicians and scientists well recognized in the field of natural medicines were involved in the writing and peer review of this scientific report on CVT-E002 (COLD-FX).

Read the American Botanical Council Therapeutic Monograph and Clinical Monograph Overview for CVT-E002 (COLD-FX)... click here


COLD-FX® Extra Strength
CVT-E002
Natural Health Product

Each capsule is certified to contain 300 mg of CVT-E002, a proprietary ChemBioPrint (CBP) product containing greater than 80% poly-furanosyl-pyranosyl-saccharides extracted from Panax quinquefolius (North American ginseng, root).

As a ChemBioPrint product, proprietary standardization technology has been used to identify and isolate the active ingredient (CVT-E002) and ensure consistency from batch to batch. CVT-E002 is scientifically proven to provide health benefits by enhancing the immune system’s viral-fighting Natural Killer cells and macrophages.

Learn more about ChemBioPrint.

Recommended use or purpose: For boosting the immune system, at the first sign of cold or flu symptoms.

Dosing, Administration and Storage:
Dosage form: capsule
Quantity per dosage unit: 300 mg
Route of administration: oral
Recommended dose: Adults and children (12 years and older):
Day 1: take 3 capsules 2 times during the day (total = 6 capsules)
Day 2: take 2 capsules 2 times during the day (total = 4 capsules)
Day 3: take 1 capsule 2 times during the day (total = 2 capsules)
Shelf Life: 5 years at room temperature

Risk Information:
Individuals requiring anti-coagulant therapy such as warfarin should avoid use of COLD-FX Extra Strength.
Do not use if pregnant or breastfeeding.
Not recommended for individuals with impaired liver or renal function.
Do not exceed the recommended daily dose.
Individuals with known allergies to ginseng should avoid use of COLD-FX Extra Strength.

 
   
Home Contact Us Privacy Policy Terms of Use Site Map Français 中文
Visit our corporate web site afexa.com
This web site is not intended for residents of the United States.
To visit the US website click here COLD-FX United States

© Afexa Life Sciences Inc. (2010) All rights reserved.
TM/® owned by Afexa Life Sciences Inc. unless otherwise marked
*Pharmacy Post Annual Survey on OTC Counseling & Recommendations, 2008.
**The Medical Post Annual Survey on OTC Counseling and Recommendations, 2008.